Jane Meisel
Academic Appointment
- Professor, Department of Gynecology & Obstetrics, Emory University School of Medicine
- Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MD from Harvard University, Cambridge
- BA from Harvard College
Research
Publications
-
Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.
Clin Breast Cancer Volume: 25 Page(s): 261 - 267.e1
04/01/2025 Authors: Goldfarb SB; Sammons SL; Meisel JL; Pluard TJ; Jenkins SN; Komm BS; Carroll D; Portman DJ -
ASO Visual Abstract: Commission on Cancer Center Performance with the New Breast Cancer Quality Measures: A Review of Historical Data.
Ann Surg Oncol Volume: 32 Page(s): 2112 - 2113
03/01/2025 Authors: Fefferman ML; Thompson DM; Wilke LG; Hwang S; Bleicher R; Freedman LM; Meisel JL; Kuchta K; Yao K -
Commission on Cancer Center Performance with the New Breast Cancer Quality Measures: A Review of Historical Data.
Ann Surg Oncol Volume: 32 Page(s): 2045 - 2055
03/01/2025 Authors: Fefferman ML; Thompson DM; Wilke LG; Hwang S; Bleicher R; Freedman LM; Meisel JL; Kuchta K; Yao K -
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
JCO Oncol Pract Volume: 21 Page(s): 351 - 357
03/01/2025 Authors: Waks AG; Chen EL; Graham N; Frey AM; Almeida K; Attaya V; Ryding C; Abbass I; Fung A; Sussell J -
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.
Sci Rep Volume: 15 Page(s): 7220
02/28/2025 Authors: Jones V; Yin HH; Yuan Y-C; Wang Y; Li SM; Aljaber D; Sanchez A; Quinones C; Schmolze D; Yuan Y -
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-nave early-stage triple negative or HR-low/HER2- breast cancer.
Ther Adv Med Oncol Volume: 17 Page(s): 17588359251316176
01/01/2025 Authors: McArthur HL; Tolaney SM; Dent R; Schmid P; Asselah J; Liu Q; Meisel JL; Niikura N; Park YH; Werutsky G -
Drug-drug interactions between palbociclib and proton pump inhibitors inearly breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
ESMO Open Volume: 10 Page(s): 104096
01/01/2025 Authors: Agostinetto E; Pfeiler G; Hlauschek D; Mayer EL; Lambertini M; de Azambuja E; Bellet-Ezquerra M; Meisel JL; Rubovszky G; Zdenkowski N -
Genomic and transcriptomic landscape of HER2-low breast cancer.
Breast Cancer Res Treat Volume: 209 Page(s): 323 - 330
01/01/2025 Authors: Bansal R; Adeyelu T; Elliott A; Walker P; Bustos MA; Rodriguez E; Accordino MK; Meisel J; Gatti-Mays ME; Hsu E -
Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.
JCO Precis Oncol Volume: 8 Page(s): e2400289
12/01/2024 Authors: Bansal R; Adeyelu T; Elliott A; Tan AR; Ribeiro JR; Meisel J; Oberley MJ; Graff SL; Sledge GW; Grilley-Olson JE -
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Nat Med Volume: 30 Page(s): 3728 - 3736
12/01/2024 Authors: Khoury K; Meisel JL; Yau C; Rugo HS; Nanda R; Davidian M; Tsiatis B; Chien AJ; Wallace AM; Arora M